Number of the records: 1
Association of PAX5 Expression with Clinical Outcome in Patients with TaT1 Transitional Cell Carcinoma of the Bladder
- 1.
SYSNO ASEP 0089478 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Association of PAX5 Expression with Clinical Outcome in Patients with TaT1 Transitional Cell Carcinoma of the Bladder Title Korelace produkce PAX5 s klinickým stavem pacientů s nádory močového měchýře stádií TaT1 Author(s) Babjuk, M. (CZ)
Soukup, V. (CZ)
Mareš, J. (CZ)
Dušková, J. (CZ)
Pecen, Ladislav (UIVT-O) RID, SAI, ORCID
Pešl, M. (CZ)
Pavlík, I. (CZ)
Dvořáček, J. (CZ)Source Title Urology. - : Elsevier - ISSN 0090-4295
Roč. 67, č. 4 (2006), s. 756-761Number of pages 7 s. Language eng - English Country US - United States Keywords bladder carcinoma ; PAX5 expression Subject RIV BB - Applied Statistics, Operational Research R&D Projects NR8095 GA MZd - Ministry of Health (MZ) NR8934 GA MZd - Ministry of Health (MZ) CEZ AV0Z10300504 - UIVT-O (2005-2011) UT WOS 000237054800027 EID SCOPUS 33646472153 DOI 10.1016/j.urology.2005.10.053 Annotation The PAX5 expression was found in 82.7% patients with bladder cancer but in no patient from the control group. The 3-year recurrence-free and progression-free survival rates in highly positive patients (PAX5 <= 0.2) were 13.2% and 71.6% compared to 40.6% and 92.8% in patients with PAX5 < 0.2 therefore PAX5 seems to be connected with the risk of tumor recurrence and progression (proved as stat. significant via log-rank test and Cox' model). Workplace Institute of Computer Science Contact Tereza Šírová, sirova@cs.cas.cz, Tel.: 266 053 800 Year of Publishing 2008
Number of the records: 1